The PREP Act SHIELDED Pharma Pipelines

💩 Pumping it out 💩

In light of our new PREP Act declaration amendments, I thought it might be fun to look and see what beautiful new herd culling murder shots “vaccines” might be in our future.

---

PLEASE DO NOT MISUNDERSTAND THIS POST.

ANY PHARMACEUTICAL PRODUCT COUNTERMEASURE THAT GETS DEPLOYED FOR THE “HEALTH THREAT” DU JOUR IS COMPLETELY SHIELDED FROM ANY LIABILITY.

OUR GOVERNMENT HAS DONE THIS.

NOT PFIZER. NOT MODERNA. NOT MERCK.

---

As you read this, and see all of the potential drugs coming down the line, KNOW that our government has already told these companies, by way of the current PREP Act declaration, that standard approval processes, oversight/regulation, gMP, contracts, distribution…all of it, is DRASTICALLY reduced, altered, or nixed entirely.

So when you get mad, direct your anger at the “stewards” of this country that have permitted legal structures to be put into place that allow for this. Familiarize yourself with the meetings concerning EUA that happened, SPECIFICALLY addressing the need to usurp standard procedure, in order to give unapproved products to PEOPLE.

HHS Workshop MCM Dispensing, EUA and the Postal Model

“EUA has a broader use beyond enabling the use of an unapproved product or extending the use of an approved product to populations for which it was not approved. In particular, it can also be used to address labeling requirements and other challenges that arise because of constraints inherent in a public health response.” ‘From a legal perspective, there are a lot of situations where EUA helps get past all those requirements,’ said [Susan E. Sherman, J.D., M.S., a senior attorney with the Office of the General Counsel, HHS] ‘You can change the labeling. You can change the information. You can change the dosage. You can give it to populations for which wasn’t approved.’ ”

All that being said….let’s have a look at what’s in store...

---

Being that mRNA is all the rage these days…

AND Moderna is LITERALLY named after it (modified + RNA)…

We’re making biotech history

Messenger RNA is not new technology, but we are discovering new ways to use it to treat and prevent illnesses and diseases. Since our founding in 2010, we have worked to build the industry's leading mRNA technology platform. 

I thought I’d start with Moderna.

Moderna Pipeline

No real surprises here… however, I find Nipah Virus notable. Why?

This will be shocking…but in an amazing coincidence, there was a recent Notice of Award of a Single-Source Cooperative Agreement regarding Nipah Virus. On August 8, 2023, The Centers for Disease Control and Prevention (CDC) announced the award of approximately $6,000,000, for Year 1 funding to icddr,b.

What luck that the vaccine is just beginning Phase 2 clinical trials!

This funding will execute critical ongoing studies on pathogens having pandemic potential such as Nipah virus.

Awesome sauce. Nipah’s not on the declaration amendment, but stay tuned…we’ve got a phase 2 trial in the works. And this…

‘Nipah virus mortality rate very high than Covid-19’: ICMR director general

According to the ICMR DG, India will be procuring 20 more doses of monoclonal antibody from Australia for the treatment of Nipah virus infection.

Sep 15, 2023 09:36 PM IST

The symptoms of the Nipah virus are similar to Covid-19 - cough, sore throat, dizziness, drowsiness, muscle pain, tiredness, encephalitis (swelling of the brain), headache, stiff neck, sensitivity to light, mental confusion, and seizures.

Side note…if you’re still getting flu shots and trying to avoid mRNA, might be time to rethink the flu jab.

Now this.

Why is this interesting (other than the part about how they just injected two thirds of the world with a bioweapon that basically gives you AIDS, if you don’t die suddenly or end up with turbo cancer)?

Well…

COVID-19, Ebola virus disease, and Nipah virus infection reclassification as novel acute immune dysrhythmia syndrome (n-AIDS): potential crucial role for immunomodulators

• DOI: 10.1007/s12026-021-09219-y

Abstract

In this manuscript, COVID-19, Ebola virus disease, Nipah virus infection, SARS, and MERS are suggested to be considered for a novel immunological reclassification as acute onset immune dysrhythmia syndrome (n-AIDS) due to altered monocytic, Th1/Th2, as well as cytokines and chemokines balances. n-AIDs is postulated to be the cause of the acute respiratory distress and multi-inflammatory syndromes which are described with fatal COVID-19, and immunomodulators are suggested to effectively manage the mentioned diseases as well as for other disorders caused by Th1/Th2 imbalance. Meanwhile, para COVID syndrome is suggested to describe various immune-related complications, whether before or after recovery, and to embrace a potential of a latent infection, that might be discovered later, as occurred with Ebola virus disease. Finally, our hypothesis has evolved out of our real-life practice that uses immunomodulatory drugs to manage COVID-19 safely and effectively.

---

Ok…to be clear, this is NOT traditional AIDS (acquired immune deficiency syndrome). But, it’s sounds preeeeetttty similar. In fact, the first work cited was this:

A T_H1→T_H2 switch is a critical step in the etiology of HIV infection.

This viewpoint proposes that an imbalance in the T_H1-type and T_H2-type responses contributes to the immune dysregulation associated with HIV infection, and that resistance to HIV infection and/or progression to AIDS is dependent on a T_H > T_H2 dominance.

---

Moving on…

Merck Pipeline

Merck already has an Ebola Vaccine, and it’s already listed as a “covered countermeasure” in the PREP declaration. PHEW. So we’ll just be waiting on a beautiful mRNA version…coming soon, I’m sure.

U.S. FDA Approves Merck’s ERVEBO® (Ebola Zaire Vaccine, Live) for Use in Children 12 Months of Age and Older

---

⬇️ SOMETHING TO NOTE REGARDING THE EBOLA VACCINE ALREADY AVAILABLE ⬇️

---

Transmission
Vaccine virus RNA has been detected by RT-PCR in blood, saliva, urine, and fluid from skin vesicles of vaccinated individuals. Transmission of vaccine virus is a theoretical possibility.

---

Also notable in Merck’s pipeline:

Dengue…who cares?

Now, you guys aren’t going to believe this….but we’ve got ANOTHER Notice of Award of a Single-Source Cooperative Agreement! Coincidences all around!

The Centers for Disease Control and Prevention (CDC) announced on January 11, 2023 the award of approximately $4,000,000. The award will continue support to PAHO in developing and implementing coordinated national and regional public health programs in the Americas that are consistent with the World Health Organization's International Health Regulations (IHR) strategies and the CDC global health priorities for.… developing improved prevention and control strategies for infectious disease, such as arboviruses, coronaviruses, chikungunya, dengue, yellow fever, Zika, HIV, poxviruses, foodborne,Dengue Fever.

Pfizer Pipeline

Pfizer oddly doesn’t have any hemorrhagic fever vaccines in the pipeline, which surprised me.

They are awfully tied up in lawsuits that will go nowhere….

OH, and they’re super busy with the turbo cancer and heart issues that just “suddenly” happened to the world.

Pfizer seems to be focusing their efforts on raking in money from the turbo cancer and cardiac issues caused by the herd culling murder shots.

Also…I’m no deep insider, but I bet there’s a reason that Pfizer is being pitched as The Big Bad Guy and is getting sued and stuff. I bet it’s not an accident that they don’t have a single mRNA vaccine in the pipeline.

Moderna’s pipeline is full though. Of mRNA.

And I also haven’t heard about many Moderna suits. Weird.

Now, let’s see what biologics got FDA approval in 2023, shall we?

FDA 2023 Biological Approvals

CYFENDUS
Anthrax Vaccine Adsorbed, Adjuvanted Indicated for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age when administered in conjunction with recommended antibacterial drugs.125761/0Emergent Product Development Gaithersburg Inc.
300 Professional Drive
Gaithersburg, MD 20879
Lic. # 208907/20/2023

ERVEBO
Ebola Zaire Vaccine, LiveTo extend the indication for use to include individuals 12 months of age and older.125690/55Merck Sharp & Dohme LLC
351 N. Sumneytown Pike
P.O. Box 1000
North Wales, PA 19454
Lic. # 000207/27/2023

DENGVAXIA
Dengue Tetravalent Vaccine, LiveTo include safety and efficacy data that support the use of DENGVAXIA in individuals 6 through 16 years of age with laboratory-confirmed previous dengue infection and living in endemic areas.125682/40Sanofi Pasteur Inc.
Discovery Drive
Swiftwater, PA 18370
Lic. # 172506/30/2023

FDA 2023 Diagnostic Approvals

Access HIV Ag/Ab combo
Access HIV Ag/Ab combo Calibrators
Access HIV Ag/Ab combo QC
Human immunodeficiency virus (HIV) serological diagnostic and/or supplemental testThe Access HIV Ag/Ab combo assay.
The Access HIV Ag/Ab combo assay is intended to be used as an aid in the diagnosis of HIV-1 and/or HIV-2 infection, including acute or primary HIV-1 infection. The assay may also be used as an aid in the diagnosis of HIV-1 and/or HIV-2 infection in pregnant women.
Chaska, MN 5531807/27/2023

Elecsys HIV Duo
Human immunodeficiency virus (HIV) serological diagnostic and/or supplemental testElecsys HIV Duo is an immunoassay intended for the in vitro simultaneous qualitative detection and differentiation of HIV-1 p24 antigen and antibodies to HIV, HIV-1 (groups M and O) and HIV-2 in human serum and plasma. Elecsys HIV Duo assay is intended to be used as an aid in the diagnosis of HIV-1 and/or HIV-2 infection, including acute or primary HIV-1 infection. The assay may also be used as an aid in the diagnosis of HIV-1/HIV-2 infection in subjects greater than 2 years of age and in pregnant women. Elecsys HIV Duo is not intended for the screening of donors of blood and blood components or human cells, tissues, and cellular and tissue-based products (HCT/Ps).
BK230804/0Roche Diagnostics
9115 Hague Road
Indianapolis, IN 4625604/04/2023

---

Anthrax, Marburg-bola, Dengue, and HIV.

Going to be so hot in 2024…

Covid is sooooo last yearssss.

---

Let’s do a quick PREP Act declaration review…

Section VI, Covered Countermeasures

The PREP Act states that a “Covered Countermeasure” must be: A “qualified pandemic or epidemic product,” or a “security countermeasure,” as described immediately below; or a drug, biological product or device authorized for emergency use in accordance with sections 564, 564A, or 564B of the FD&C Act.

A security countermeasure is a drug or device, as defined in the FD&C Act or a biological product, as defined in the PHS Act that: (i) (a) The Secretary determines to be a priority to diagnose, mitigate, prevent, or treat harm from any biological, chemical, radiological, or nuclear agent identified as a material threat by the Secretary of Homeland Security, or (b) to diagnose, mitigate, prevent, or treat harm from a condition that may result in adverse health consequences or death and may be caused by administering a drug, biological product, or device against such an agent; and (ii) is determined by the Secretary of Health and Human Services to be a necessary countermeasure to protect public health.

Section VI lists the Ebola Virus Disease Vaccines that are Covered Countermeasures. The Secretary is amending the list to identify the vaccines without names of manufacturers. This change is intended to clarify that the listed vaccines are Covered Countermeasures regardless of the arrangements made by manufactures for production of the vaccine. The change is intended to clarify existing coverage; it is not intended to be a substantive legal change. In addition, the Secretary changed “BPSC1001 (rVSV–ZEBOV–GP)” to the current name for the same vaccine, “Recombinant Vesicular Stomatitis Virus-vectored vaccine expressing EBOV-Zaire glycoprotein (rVSV–ZEBOV–GP),” for accuracy.

Thus, it is the Secretary's interpretation that, when a Declaration is in effect, the Act precludes, for example, liability claims alleging negligence by a manufacturer in creating a vaccine, or negligence by a health care provider in prescribing the wrong dose, absent willful misconduct. Likewise, the Act precludes a liability claim relating to the management and operation of a countermeasure distribution program or site, such as a slip-and-fall injury or vehicle collision by a recipient receiving a countermeasure at a retail store serving as an administration or dispensing location that alleges, for example, lax security or chaotic crowd control.

---

Hey guys, I wonder if those severely compromised immune systems from the herd culling murder shots all that damage from covid will make faking a pandemic easier people more susceptible to Big Scary Viruses?

Seems like the murders of the world might be planning on it….

Click image to purchase